• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Indivior PLC

    10/4/24 6:01:38 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INDV alert in real time by email
    SC 13D 1 ef20036708_sc13d.htm SC 13D

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     


    SCHEDULE 13D
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.)*



    INDIVIOR PLC
    (Name of Issuer)

    Ordinary Shares, $0.50 nominal value per share
    (Title of Class of Securities)

    G4766E116
    (CUSIP Number)

    Richard Ting
    General Counsel & Managing Director
    Oaktree Capital Group Holdings GP, LLC
    333 South Grand Avenue, 28th Floor
    Los Angeles, California 90071

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
     
    October 2, 2024
    (Date of Event Which Requires Filing of this Statement)
     


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-l(e), 240.13d-l(f) or 240.13d-l(g), check the following box. ☒
     
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including

    all exhibits. See §240 13d-7 for other parties to whom copies are to be sent.

    1       The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     

    *
    information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes’).
     


    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Value Opportunities Fund, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    5,438,996
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    5,438,996
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    5,438,996
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    4.1%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     
     

    1)
    Calculated based on 133,895,931 Ordinary Shares outstanding as of July 12, 2024, as disclosed in the Issuer’s Form 6-K filed with the Securities and Exchange Commission (the “SEC”) on July 16, 2024.


    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree London Liquid Value Opportunities Fund (VOF), L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    2,351,370
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    2,351,370
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    2,351,370
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    1.8%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     


    1)
    Calculated based on 133,895,931 Ordinary Shares, outstanding as of July 12, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on July 16, 2024.
     

    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Phoenix Investment Fund, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    268,780
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    268,780
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    268,780
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.2%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     
     
    (1)
    Calculated based on 133,895,931 Ordinary Shares, outstanding as of July 12, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on July 16, 2024.
     

    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Capital Management, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☒

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,316,274
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,316,274
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,316,274
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    1.0%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     
     
    (1)
    Calculated based on 133,895,931 Ordinary Shares, outstanding as of July 12, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on July 16, 2024.
     

    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Fund GP I, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    8,059,146
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    8,059,146
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    8,059,146
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    6.0%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     
     
    (1)
    Calculated based on 133,895,931 Ordinary Shares, outstanding as of July 12, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on July 16, 2024.
     

    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Capital Holdings, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    9,375,420
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    9,375,420
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    9,375,420
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    7.0%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
     
    (1)
    Calculated based on 133,895,931 Ordinary Shares, outstanding as of July 12, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on July 16, 2024.


    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Capital Group Holdings GP, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    9,375,420
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    9,375,420
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    9,375,420
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    7.0%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
     
    (1)
    Calculated based on 133,895,931 Ordinary Shares, outstanding as of July 12, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on July 16, 2024.
     

    1
    NAMES OF REPORTING PERSONS
     
     
    Brookfield Asset Management ULC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    British Columbia, Canada
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    9,375,420
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    9,375,420
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    9,375,420
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    7.0%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)
    Calculated based on 133,895,931 Ordinary Shares, outstanding as of July 12, 2024, as disclosed in the Issuer’s Form 6-K filed with the SEC on July 16, 2024.
     

    Item 1.
    Security and Issuer
     
    This Schedule 13D (this “Schedule 13D”) relates to the Ordinary Shares, $0.50 nominal value per share (the “Ordinary Shares”), of Indivior PLC, a public limited company organized under the laws of England and Wales (the “Issuer”), with its principal executive offices located at 10710 Midlothian Turnpike, Suite 125, North Chesterfield, VA 23235.
     
    Item 2.
    Identity and Background
     
    (a)-(c), (f)
    This Schedule 13D is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):
     
     
    (i)
    Oaktree Value Opportunities Fund, L.P (“OVO Fund”);
     
    (ii)
    Oaktree London Liquid Value Opportunities Fund (VOF), L.P. (“VOF”);
     
    (iii)
    Oaktree Phoenix Investment Fund, L.P. (“OPI Fund”);
     
    (iv)
    Oaktree Capital Management, L.P. (“OC Management”);

    (v)
    Oaktree Fund GP I, L.P. (“Oaktree GP I”), as indirect general partner of OVO Fund, VOF and OPI Fund;

    (vi)
    Oaktree Capital Holdings, LLC (“OC Holdings”), as indirect general partner of OVO Fund, VOF, OPI Fund and Oaktree GP I;

    (vii)
    Oaktree Capital Group Holdings GP, LLC (“OC Group Holdings” and, together with each of the foregoing, the “Oaktree Entities”), in its capacity as the indirect owner of Class B Units of OC Holdings;
     
    (viii)
    Brookfield Asset Management ULC (“Brookfield”).
     
    The principal business of Brookfield is operations as a leading global alternative asset manager. The principal business address of Brookfield is Brookfield Place, Suite 100, 181 Bay Street, P.O. Box 762, Toronto, Ontario, Canada M5J 2T3.
     
    The principal business of the Oaktree Entities is investment management, specializing in alternative investments.  The principal business address of the Oaktree Entities is 333 S. Grand Avenue, 28th Floor, Los Angeles, CA 90071.
    (d)-(e)
    With respect to each of the Reporting Persons, (i) during the last five years, the Reporting Person has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors); and (ii) except as set forth below, during the last five years, the Reporting Person has not been party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
     
    On September 25, 2024, the SEC accepted an offer by OC Management to resolve an investigation involving Sections 13(d) and 16(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rules 13d-2 and 16a-3 thereunder, which require certain investors, like the Reporting Persons, that beneficially own the registered equity securities of a public company to file reports with the SEC of their beneficial ownership in the equity of the company, including changes in their beneficial ownership, within specified timeframes.  OC Management cooperated immediately and fully with the SEC’s investigation, and, without admitting or denying the SEC’s findings, in a settled proceeding agreed to cease and desist from committing or causing any violations and any future violations of Sections 13(d) and 16(a) of the Exchange Act and Rules 13d-2 and 16a-3 thereunder and to pay a $375,000 penalty.
     

    Item 3.
    Source and Amount of Funds or Other Consideration
     
    The securities reported herein and described in more detail in Item 4 were purchased with working capital in open market transactions.
     
    Item 4.
    Purpose of Transaction.
     
    The Reporting Persons acquired the Ordinary Shares for investment purposes. The Reporting Persons intend to review their investment in the Issuer on an ongoing basis and, in the course of their review, may take actions (including through their affiliates) with respect to their investment or the Issuer, including communicating with the board of directors of the Issuer (the “Board”), members of management or other security-holders of the Issuer, or other third parties from time to time, and taking steps to implement a course of action, including, without limitation, engaging advisors, including legal, financial, regulatory, technical and/or industry advisors.

    The Reporting Persons intend to engage in discussions with the Board and management of the Issuer regarding opportunities to enhance stockholder value, including through changes to the Issuer’s capital allocation and capital structure, and exploration of strategic alternatives, including, without limitation, a potential sale of the Issuer.

    The Reporting Persons also may engage in discussions and take other actions relating to various alternative courses of action, including, without limitation, those related to potential business combinations or dispositions involving the Issuer or any of its subsidiaries, or their businesses or assets, including transactions in which the Reporting Persons may seek to participate and potentially engage in; changes in the present business, operations, strategy, future plans or prospects of the Issuer, financial or governance matters; changes to the Board (including board composition) or management of the Issuer; changes to the capitalization, ownership structure, dividend policy, business or corporate structure or governance documents of the Issuer; de-listing or de-registration of the Issuer’s securities, or any action similar to those enumerated above.

    The Reporting Persons or their affiliates may seek to acquire some or all securities of the Issuer, including Ordinary Shares and/or other equity, debt, notes or other financial instruments related to the Issuer or the Ordinary Shares (which may include rights or securities exercisable or convertible into securities of the Issuer), and/or sell or otherwise dispose of some or all of such Issuer securities or financial instruments (which may include distributing some or all of such securities to such Reporting Person’s respective partners or beneficiaries, as applicable) from time to time, in each case, in open market or private transactions, block sales or otherwise. Any transaction that any of the Reporting Persons or their affiliates may pursue will depend on a variety of factors, including, without limitation, the price and availability of the Issuer’s securities or other financial instruments, the Reporting Persons’ or such affiliates’ trading and investment strategies, subsequent developments affecting the Issuer, the Issuer’s business and the Issuer’s prospects, other investment and business opportunities available to such Reporting Persons and their affiliates, general industry and economic conditions, the securities markets in general, tax considerations and other factors deemed relevant by such Reporting Persons and such affiliates.
     
    None of the Reporting Persons, and to the best of their knowledge, none of the Covered Persons, has any current plan or proposal which relate to or would result in any of the matters described in Items 4(a) - (j) of Schedule 13D, except as described in this Schedule 13D or as would occur upon, in connection with completion of, or following, any of the actions described in this Schedule 13D
     

    Item 5.
    Interest in Securities of the Issuer.
     
    (a), (b) and (c)
    The information set forth in rows (7) through (11) of the cover pages of this Schedule 13D is incorporated by reference into this Item 5.
     
    The Reporting Persons hold an aggregate of 9,375,420 shares of Common Stock, representing 7.0% of the Common Stock outstanding as of the date hereof. All such ownership percentages of the securities reported herein are calculated assuming 133,895,931 Ordinary Shares outstanding as reported by the Issuer in its Form 6-K filed with the SEC on July 16, 2024.
     
    In this regard, OVO Fund is the direct holder of 5,438,996 Ordinary Shares. VOF Fund is the direct holder of 2,351,370 Ordinary Shares. OPI Fund is the direct holder of 268,780 Ordinary Shares. OC Management is the investment manager to Boston Patriot Arlington St LLC, an SMA account which directly holds 1,316,274 Ordinary Shares. Oaktree GP I is the indirect general partner of OVO Fund, VOF, and OPI Fund, and as such may be deemed to beneficially own an aggregate of 8,059,146 Ordinary Shares. OC Holdings is the indirect general partner of OVO Fund, VOF, OPI Fund, and Oaktree GP I, and as such may be deemed to beneficially own an aggregate of 9,375,420 Ordinary Shares. OC Group Holdings is the indirect owner of the Class B Units of OC Holdings, and as such may be deemed to beneficially own an aggregate of 9,375,420 Ordinary Shares. Brookfield is the indirect owner of the Class A1 Units OC Holdings, and as such may be deemed to beneficially own an aggregate of 9,375,420 Ordinary Shares. Each of the Reporting Persons disclaims beneficial ownership of the reported securities and the filing of this Statement shall not be construed as an admission of such beneficial ownership for the purposes of Section 13(d) or 13(g) of the Exchange Act.
     
    Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission by any of the Reporting Persons that it is the beneficial owner of any of the Common Stock referred to herein for the purposes of Section 13(d) of the Act, or for any other purpose.
     
    Item 6.
    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
     
    Not Applicable.
     
    Item 7.
    Material to be Filed as Exhibits
     
    Exhibit 24.1
    Joint Filing Agreement, dated as of October 3, 2024, by and among the reporting persons.


    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Dated: October 3, 2024
     
     
    OAKTREE VALUE OPPORTUNITIES FUND, L.P.
     

     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    OAKTREE LONDON LIQUID VALUE OPPORTUNITIES FUND (VOF), L.P.
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    OAKTREE PHOENIX INVESTMENT FUND, L.P.
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    OAKTREE CAPITAL MANAGEMENT, L.P.
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    OAKTREE FUND GP I, L.P.
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    OAKTREE CAPITAL HOLDINGS, LLC
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory


     
    OAKTREE CAPITAL GROUP HOLDINGS GP, LLC
         
     
    By:
    /s/ Henry Orren
     
    Name:
    Henry Orren
     
    Title:
    Authorized Signatory

     
    BROOKFIELD ASSET MANAGEMENT ULC
         
     
    By:
    /s/ Kathy Sarpash
     
    Name:
    Kathy Sarpash
     
    Title:
    Managing Director, Legal & Regulatory



    Get the next $INDV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INDV

    DatePrice TargetRatingAnalyst
    1/28/2025$16.00Buy
    Rodman & Renshaw
    7/23/2024$22.00Overweight
    Piper Sandler
    4/3/2024$37.00Buy
    Craig Hallum
    7/13/2023$35.00Outperform
    Northland Capital
    More analyst ratings

    $INDV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

      SLOUGH, England and RICHMOND, Va., June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List (the "Official List") of the U.K. Financial Conduct Authority ("FCA"); and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's ("LSE") main market for listed securities (together, the "London Delisting"). Background to and Reasons for the London Delisting In the circula

      6/2/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Patrick Barry as Chief Commercial Officer

      Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va., May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. In this role, Barry will lead the company's commercial growth strategy, execution, and operations as Indivior continues its mission to transform the treatment of opioid use disorder led by SUBLOCADE® (buprenorphine extended-release) Injection. Barry will join Indivior's executive committee. "Patrick is an accomplished and resp

      5/27/25 8:30:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior to Participate in Upcoming Investor Events

      RICHMOND, Va., May 13, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor events: Jefferies Global Healthcare Conference – New York City, NYJoe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Wednesday, June 4th. Joe Ciaffoni will also participate in a fireside discussion on Wednesday, June 4th at 9:55 a.m. U.S. ET. Interested investors should contact their Jefferies representative to schedule a meeting. The fireside discussion will be publicly

      5/13/25 10:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Indivior PLC

      SC 13G - INDIVIOR PLC (0001625297) (Subject)

      11/15/24 6:03:54 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Indivior PLC

      SC 13G/A - INDIVIOR PLC (0001625297) (Subject)

      11/14/24 5:00:25 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Indivior PLC

      SC 13D/A - INDIVIOR PLC (0001625297) (Subject)

      11/7/24 8:23:16 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Leadership Updates

    Live Leadership Updates

    See more
    • Indivior Announces Patrick Barry as Chief Commercial Officer

      Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va., May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. In this role, Barry will lead the company's commercial growth strategy, execution, and operations as Indivior continues its mission to transform the treatment of opioid use disorder led by SUBLOCADE® (buprenorphine extended-release) Injection. Barry will join Indivior's executive committee. "Patrick is an accomplished and resp

      5/27/25 8:30:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Further Changes to Board of Directors

      RICHMOND, Va., March 4, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) ("Indivior" or the "Company") today announced that, further to the announcement on December 17, 2024 of certain Director arrangements agreed with Oaktree Capital Management L.P. ("Oaktree"), the announcement on January 28, 2025 of the appointment of Dr. David Wheadon as Chair of the Company, the announcement on February 3, 2025 of the appointment of Daniel Ninivaggi as an Independent Non-Executive Director of the Company, and the announcement on February 27, 2025 of the appointment of Joe Ciaffoni as Chief Executive Officer of the Company, and following further discussions with Oaktree, the Company has agreed to m

      3/4/25 8:40:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    SEC Filings

    See more
    • SEC Form 8-K filed by Indivior PLC

      8-K - INDIVIOR PLC (0001625297) (Filer)

      6/2/25 6:06:09 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior PLC filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - INDIVIOR PLC (0001625297) (Filer)

      5/30/25 6:51:16 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Indivior PLC

      SCHEDULE 13D/A - INDIVIOR PLC (0001625297) (Subject)

      5/22/25 4:45:47 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Indivior with a new price target

      Rodman & Renshaw initiated coverage of Indivior with a rating of Buy and set a new price target of $16.00

      1/28/25 7:14:13 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Indivior with a new price target

      Piper Sandler initiated coverage of Indivior with a rating of Overweight and set a new price target of $22.00

      7/23/24 6:29:18 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum initiated coverage on Indivior with a new price target

      Craig Hallum initiated coverage of Indivior with a rating of Buy and set a new price target of $37.00

      4/3/24 7:45:35 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Financials

    Live finance-specific insights

    See more
    • Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

      SLOUGH, England and RICHMOND, Va., June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List (the "Official List") of the U.K. Financial Conduct Authority ("FCA"); and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's ("LSE") main market for listed securities (together, the "London Delisting"). Background to and Reasons for the London Delisting In the circula

      6/2/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Q1 2025 Financial Results

      SLOUGH, United Kingdom and RICHMOND, Va., April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com

      4/24/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces FY and Q4 2024 Financial Results

      SLOUGH, United Kingdom and RICHMOND, Va., Feb. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.c

      2/20/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care